Source:http://linkedlifedata.com/resource/pubmed/id/10466733
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1999-10-21
|
pubmed:abstractText |
This study evaluated cerebral phosphorus metabolites in opiate-dependent polydrug abusers in methadone maintenance therapy (MMT) and determined whether metabolite profiles differed based on treatment duration. Phosphorus magnetic resonance spectroscopy (31P-MRS) data were acquired with the ISIS volume localization method from a 50-mm thick axial brain slice through the orbitofrontal and occipital cortices. Study subjects included 15 MMT subjects, seven having undergone treatment for an average of 39 +/- 23 weeks (mean +/- S.D.) and eight having undergone treatment for 137 +/- 53 weeks, as well as an age matched comparison group (n = 16). The methadone dose administered on the study day averaged 70.5 +/- 17.1 mg and was statistically equivalent in short- and long-term subgroups. MMT subjects (n = 15) differed from control subjects in percent phosphocreatine (%PCr) levels (-13%), and in both phosphomonoester (%PME, +13%) and phosphodiester (%PDE, +10%) levels, which likely reflect abnormalities in energy and phospholipid metabolism, respectively. There were no sex effects or group by sex interaction effects on these measures. In short-term MMT treatment subjects, abnormal %PCr (-18%), %PME (+20%) and %PDE (+17%) levels were found compared with control subjects. The only metabolite abnormality detected in long-term MMT subjects was decreased %PCr (-9%), in spite of continued illicit drug abuse. From these data, we conclude that polydrug abusers in MMT have 31P-MRS results consistent with abnormal brain metabolism and phospholipid balance. The nearly normal metabolite profile in long-term MMT subjects suggests that prolonged MMT may be associated with improved neurochemistry.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0165-1781
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
30
|
pubmed:volume |
90
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
143-52
|
pubmed:dateRevised |
2008-4-17
|
pubmed:meshHeading |
pubmed-meshheading:10466733-Adult,
pubmed-meshheading:10466733-Brain,
pubmed-meshheading:10466733-Case-Control Studies,
pubmed-meshheading:10466733-Cerebrovascular Circulation,
pubmed-meshheading:10466733-Female,
pubmed-meshheading:10466733-Humans,
pubmed-meshheading:10466733-Magnetic Resonance Spectroscopy,
pubmed-meshheading:10466733-Male,
pubmed-meshheading:10466733-Methadone,
pubmed-meshheading:10466733-Middle Aged,
pubmed-meshheading:10466733-Narcotics,
pubmed-meshheading:10466733-Opioid-Related Disorders,
pubmed-meshheading:10466733-Phosphorus
|
pubmed:year |
1999
|
pubmed:articleTitle |
Cerebral phosphorus metabolite abnormalities in opiate-dependent polydrug abusers in methadone maintenance.
|
pubmed:affiliation |
Brain Imaging Center, McLean Hospital, MA 02478, USA. kaufman@mclean.org
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|